BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study Open Access
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123709
Published online Nov 15, 2026. doi: 10.4251/wjgo.123709
Clinical and molecular heterogeneity of microsatellite instability-high colorectal cancer in older adults
Tatsuya Shonaka, Chikayoshi Tani, Shoichiro Mizukami, Daisuke Koro, Hiroyoshi Iwata, Mizuho Ohara, Hideki Yokoo, Division of Gastroenterological and Transplantation Surgery, Department of Surgery, Asahikawa Medical University, Asahikawa 078-8510, Japan
Hiroki Tanabe, Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan
Hiroki Tanabe, Yoshio Makita, Department of Genetic Counseling, Asahikawa Medical University Hospital, Asahikawa 078-8510, Japan
Mishie Tanino, Department of Pathology, Asahikawa Medical University Hospital, Asahikawa 078-8510, Japan
ORCID number: Tatsuya Shonaka (0000-0001-8024-482X); Chikayoshi Tani (0009-0007-5727-8694); Shoichiro Mizukami (0009-0001-9182-8369); Daisuke Koro (0009-0003-1956-8536); Hiroyoshi Iwata (0000-0002-3970-0827); Mizuho Ohara (0009-0006-6586-0206); Hiroki Tanabe (0000-0001-9029-5081); Yoshio Makita (0000-0002-0341-5709); Mishie Tanino (0000-0003-3370-0452); Hideki Yokoo (0000-0002-6203-8528).
Author contributions: Shonaka T, Tani C, and Mizukami S contributed to study conception and design; Koro D, Iwata H, and Ohara M collected and analyzed data; Tanabe H and Makita Y provided genetic counseling and advice; Tanino M performed pathological diagnosis and mismatch repair immunostaining for pathological evaluation; Shonaka T wrote the first draft of this manuscript; Yokoo H supervised the study. All the authors critically reviewed, commented on, and approved the final manuscript.
AI contribution statement: Portions of this manuscript were edited using AI tools (specifically Gemini) solely for language refinement. The authors carefully reviewed and verified all AI-assisted outputs and take full responsibility for the scientific content of the manuscript.
Supported by Akiyama Life Science Foundation.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of Asahikawa Medical University, No. 24011.
Informed consent statement: Informed consent was obtained from all patients via an opt-out framework, in accordance with the institutional ethical requirements and the Declaration of Helsinki. Patient data were fully anonymized to protect personal information.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: The datasets supporting the conclusions of this study are available from the corresponding author upon request. Owing to ethical and confidentiality constraints, the raw datasets are not publicly available.
Corresponding author: Tatsuya Shonaka, MD, PhD, Division of Gastroenterological and Transplantation Surgery, Department of Surgery, Asahikawa Medical University, 2-1 Midorigaoka-Higashi, Asahikawa 078-8510, Japan. shonaka@asahikawa-med.ac.jp
Received: May 27, 2026
Revised: June 26, 2026
Accepted: July 16, 2026
Published online: November 15, 2026
Processing time: 162 Days and 23 Hours

Abstract
BACKGROUND

Although universal screening for Lynch syndrome is gaining increased support, the clinical utility of microsatellite instability (MSI) testing in older patients remains controversial. Consequently, MSI-high (MSI-H) colorectal cancer (CRC) in older adults is generally considered a sporadic disease driven by aging, and the actual molecular heterogeneity in this population remains underappreciated.

AIM

To define age-specific clinicopathological MSI-H CRC features in an aging East Asian population and challenge the assumption of uniformly sporadic older MSI-H CRC.

METHODS

Data of 573 consecutive patients who underwent surgical resection for primary CRC between 2013 and 2025 were retrospectively analyzed. MSI status was determined using five mononucleotide markers or mismatch repair immunohistochemistry. The patients were stratified into older (≥ 71 years; n = 289) and younger (≤ 70 years; n = 284) groups.

RESULTS

The prevalence of MSI-H CRC was comparable across groups: 7.4% in the older group and 7.6% in the younger group (P = 1.0). Although the older group had significantly more BRAF mutations (P < 0.001), the molecular landscape was heterogeneous. Of the older MSI-H patients, 28.6% (6/21) exhibited non-sporadic, atypical profiles, including four BRAF wild-type cases with MLH1 deficiency and two with MSH2 or MSH6 deficiencies. A 72-year-old patient with an MSH6 mutation was definitively diagnosed with Lynch syndrome, a condition that would have remained undetected under the conventional age-restricted screening guidelines.

CONCLUSION

Although limited by a small sample size, nearly 30% of older patients with MSI-H CRC in our cohort exhibit atypical molecular profiles, suggesting that older age does not uniformly imply sporadic disease. Relying strictly on age to triage patients carries a risk of missing Lynch syndrome. Further larger studies are needed to confirm whether reflex MLH1 promoter methylation analysis should be performed regardless of age to optimize precision medicine.

Key Words: Microsatellite instability; Colorectal cancer; Mismatch repair; Lynch syndrome; Molecular heterogeneity; Older patients

Core Tip: While microsatellite instability-high colorectal cancer in older adults is widely considered sporadic, our real-world data revealed that 28.6% (6/21) of older adults with microsatellite instability-high exhibited atypical molecular profiles, including BRAF wild-type/MLH1 and MSH2/MSH6 deficiencies. Age-based assumptions can lead to missed diagnoses of Lynch syndrome, as demonstrated in the 72-year-old patient in our study. Therefore, reflex MLH1 promoter methylation analysis should be routinely performed regardless of age to optimize precision medicine and facilitate life-saving cascade screening of family members.



INTRODUCTION

Colorectal cancer (CRC) is a heterogeneous disease classified into several molecular subtypes. Microsatellite instability-high (MSI-H) CRC is a distinct molecular subtype that accounts for 10%-15% of all CRC cases[1]. According to the consensus molecular subtype classification, MSI-H CRC corresponds to consensus molecular subtype 1 (immune subtype)[2], and is characterized by a pronounced antitumor immune response[3]. MSI-H CRC is generally associated with a favorable prognosis, particularly in patients with stage II and III disease[4,5]. However, this prognostic advantage might be attenuated by concomitant molecular alterations, such as BRAF mutations[6]. MSI-H CRC has distinct clinicopathological characteristics[7,8]. MSI-H CRC is more frequently associated with Lynch syndrome in younger patients, whereas it is predominantly sporadic and often associated with MLH1 promoter hypermethylation in older patients[9].

Based on these characteristics, the National Comprehensive Cancer Network Guidelines support MSI testing or mismatch repair (MMR) protein immunohistochemistry (IHC) as universal screening methods for Lynch syndrome in patients with CRC[10]. However, some clinical guidelines advocate selective testing in patients aged ≥ 70 years, limiting MSI evaluation to those who fulfill the revised Bethesda Guidelines[11,12]. Furthermore, universal screening may be optimally applied to patients aged ≤ 70 years for cost-effectiveness[13]. However, a definitive age threshold for MSI testing is not yet established. These age-restricted strategies implicitly rely on the assumption that older patients with MSI-H predominantly have sporadic disease, which may risk overlooking clinically meaningful atypical profiles.

Therefore, the clinical significance of MSI testing in older patients with CRC remains unclear. This study aimed to comprehensively analyze the clinicopathological features of resected MSI-H CRC in a single-center, large-scale retrospective cohort with a focus on age-stratified differences. In the context of East Asia’s rapidly aging population, we sought to challenge the widely held assumption that older MSI-H CRC cases are uniformly sporadic. We evaluated the necessity for universal screening in Japan, where the population is rapidly aging, to ensure that older patients with Lynch syndrome are not overlooked.

MATERIALS AND METHODS
Study design and patient population

This was a single-center retrospective cohort study (Figure 1). The study included 573 consecutive patients who underwent surgical resection for primary CRC at Asahikawa Medical University Hospital in Japan between January 1, 2013 and October 31, 2025, in whom either MSI testing or MMR protein IHC was performed on tumor tissue. Patients who did not undergo resection of the primary tumor were excluded. An age group threshold of 70 years was selected because this threshold is widely established in previous literature and clinical guidelines as the optimal age-limit for cost-effective universal MSI screening, balancing the diagnostic yield of Lynch syndrome against institutional and healthcare costs[11,13].

Figure 1
Figure 1 Flow diagram of patient selection. A total of 573 patients underwent surgical resection for primary colorectal cancer at Asahikawa Medical University Hospital between 2013 and 2025. Based on microsatellite instability testing or mismatch repair immunohistochemistry, 43 patients were classified as having microsatellite instability-high and 530 as having microsatellite-stable. Patients with microsatellite instability-high colorectal cancer were further stratified by age (≤ 70 and ≥ 71 years). CRC: Colorectal cancer; MSI-H: Microsatellite instability-high; MSS: Microsatellite-stable; MMR: Mismatch repair.

Among them, 43 had MSI-H CRC. The patients were stratified by age into older (≥ 71 years; n = 21) and younger (≤ 70 years; n = 22) groups. Patients with preoperative distant metastases, who received neoadjuvant chemoradiotherapy or chemotherapy, and who underwent additional surgical resection after endoscopic treatment (endoscopic submucosal dissection or resection) were excluded from the analysis.

Data collection and pathological evaluation

Clinical and pathological data, including age, sex, tumor size, tumor location, tumor-node-metastasis classification, presence of serum carcinoembryonic antigen (CEA) and carbohydrate antigens 19-9, pathological findings, such as histological type, and genetic findings (BRAF V600E and RAS), were retrospectively retrieved from electronic medical records. Tumor staging was performed according to the Union for International Cancer Control/American Joint Committee on Cancer Staging Manual, 9th edition[14]. Lymph nodes and distant metastases were evaluated as present or absent. Tumors located between the cecum and splenic flexure were classified as right-sided, whereas those distal to the splenic flexure were classified as left-sided colon cancers. All pathological evaluations were performed by experienced gastrointestinal pathologists at Asahikawa Medical University.

Tumors with mucinous or poorly differentiated components were defined as those with mucinous or poorly differentiated components, respectively. Pathological findings, including lymphatic and venous invasion and infiltrative growth patterns, were evaluated according to the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma, 3rd English edition[15]. RAS (KRAS and NRAS) and BRAF V600E mutation analyses were performed using polymerase chain reaction (PCR) assays in an externally certified laboratory according to the manufacturer’s instructions.

Assessment of MSI and Lynch syndrome

MSI status was confirmed in 573 cases using MMR protein IHC (n = 179) or PCR-based MSI testing (n = 394). In accordance with routine clinical practice, these two modalities were generally used independently based on clinical indications, rather than being performed concurrently for all patients. In cases with equivocal MMR-IHC results, MSI testing was performed to ensure diagnostic accuracy.

MSI testing was conducted using a multiplex PCR-based assay with five mononucleotide markers (BAT25, BAT26, NR21, NR24, and MONO27) (SRL Inc., Tokyo, Japan). IHC was performed using primary antibodies against MLH1 (clone M1), PMS2 (clone EPR3947), MSH2 (clone G219–1129), and MSH6 (clone 44). The MSI status was determined by MSI testing of formalin-fixed, paraffin-embedded tumor tissues or by immunohistochemical staining for MMR-related proteins (MLH1, PMS2, MSH2, and MSH6). MSI testing was performed at an externally certified laboratory using a PCR-based assay with a standard panel of microsatellite markers according to the manufacturer’s instructions. Loss of MMR protein expression was defined as the complete absence of nuclear staining in tumor cells in the presence of retained staining in the surrounding non-neoplastic cells, which served as an internal positive control. In cases of suspected Lynch syndrome, germline genetic testing was performed using peripheral blood samples for a definitive diagnosis after informed consent was obtained. In cases in which germline testing was not performed, the presumed causative gene was inferred based on the pattern of MMR protein loss identified by IHC.

In this study, “atypical molecular profiles” or “non-typical sporadic patterns” in older patients (aged ≥ 71 years) were defined as MMR-deficient/MSI-H tumors that do not fit the conventional age-related sporadic pathway (concomitant MLH1 loss and BRAF V600E mutation). The specific criteria for classification as atypical were as follows: (1) Any loss of MSH2, MSH6, or isolated PMS2 expression, or (2) MLH1 expression loss with BRAF wild-type status. The latter was included because BRAF wild-type status in MLH1-deficient tumors cannot rule out Lynch syndrome, necessitating further clinical attention.

Statistical analysis

Statistical analyses were performed using the R software and EZR (version 2.9.1). Student’s t-test was used for comparisons of mean values, and the Mann-Whitney U test was used for comparisons of median values. Data are presented as medians (range) or mean ± SD, as appropriate. Categorical variables were compared using the χ2 test or Fisher’s exact test, as appropriate. Statistical significance was set at P < 0.05.

Ethical considerations and study registration

This study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Ethics Committee of Asahikawa Medical University, No. 24011. This retrospective study used an opt-out consent form. MSI or MMR protein testing was performed as part of routine clinical practice under an opt-out consent framework, in accordance with the institutional ethical requirements. Patient data were anonymized to protect their personal information. The study was registered with the University Hospital Medical Information Network (UMIN000059530).

RESULTS
Patient characteristics

Patient characteristics are summarized in Table 1. The median age of the 573 patients included in the study was 70 years (range: 24-93 years), including 320 men and 253 women. Tubular adenocarcinoma was the predominant histological subtype, accounting for 497 (86.7%) cases. MSI-H CRC was identified in 43 patients (7.5%). An age-stratified analysis showed that the MSI-H prevalence among patients with CRC was 7.4% in patients aged ≥ 71 years and 7.6% in those aged ≤ 70 years. Fifteen patients were definitively diagnosed with Lynch syndrome based on germline genetic testing results. However, these diagnoses were limited to those who provided consent for genetic analysis. Therefore, additional cases of Lynch syndrome may have been included among patients classified as having non-Lynch syndrome.

Table 1 Clinicopathological characteristics of patients with colorectal cancer (n = 573).
Characteristics
n (%)
Age70 (24-93)
Male320 (55.8)
Female253 (44.2)
LocationRight140 (24.4)
Left433 (75.6)
Tumor size (mm)mean ± SD47.1 ± 22.9
Histological typeTubular497 (86.7)
Poorly differentiated19 (3.3)
Mucinous34 (5.9)
Medullary4 (0.7)
Papillary16 (2.8)
Other (goblet cell, endocrine)3 (0.5)
MSIMSI-H43 (7.5)
MSS530 (92.5)
MSI-H prevalence by age group≤ 70 years22/288 (7.6)
≥ 71 years21/285 (7.4)
Lynch syndrome (definitive diagnosis)15 (2.6)
Comparison between MSI-H and microsatellite-stable CRC

The clinicopathological characteristics of patients with MSI-H CRC (n = 43) and microsatellite-stable (MSS) CRC (n = 530) are shown in Table 2. Age-stratified analysis showed that patients aged ≤ 70 years accounted for 22 cases (51.2%) in the MSI-H group, a proportion comparable to that observed in the MSS group (266 cases, 50.2%). The serum CEA levels showed a lower trend in patients with MSI-H CRC than in those with MSS CRC, although the difference was not statistically significant (P = 0.061). Compared with MSS, MSI-H CRC occurred significantly more frequently in the right colon (P < 0.001) and contained mucinous components (P < 0.001). Genetic analysis revealed that MSI-H CRC was more frequently associated with RAS wild-type status (P = 0.001) and BRAF mutations (P < 0.001). MSI-H CRC demonstrated significantly lower rates of lymph node and distant metastases than MSS CRC (both P < 0.001). In addition, MSI-H CRC was less frequently associated with venous invasion (P = 0.041), and more commonly exhibited an expansive growth pattern (P = 0.041).

Table 2 Comparison of clinicopathological characteristics between microsatellite instability-high and microsatellite stability colorectal cancer, median (range)/n (%).
Characteristics
MSI-H (n = 43)
MSS (n = 530)
P value
Age70 (30-89)70 (24-93)0.638
≥ 71 years21 (48.8)264 (49.8)1
Sex0.206
Male20 (46.5)300 (56.6)
Female23 (53.5)230 (43.4)
CEA (ng/mL)3.3 (0.6-107)3.8 (0.5-1736)0.061
CA19-9 (U/mL)13 (2-440)12 (1-43749)0.421
Tumor location< 0.001
Right/left31/12109/421
Genetic findings
RAS31/8/4270/237/230.001
Wild/mut/NA
BRAF V600E22/16/5495/7/28< 0.001
Wild/mut/NA
Pathological findings
Histological type22/6/10/4/1/0475/13/24/0/15/3< 0.001
Tub/por/muc/med/pap/other
Mucinous component< 0.001
Yes/no31/12132/398
Poorly component0.334
Yes/no14/29216/314
Tumor size (mm), mean ± SD52.0 ± 31.646.7 ± 22.10.148
T0/5/9/25/45/45/71/326/830.458
0/1/2/3/4
Lymph node metastasis< 0.001
No/yes34/9277/253
Distant metastasis< 0.001
No/yes42/1462/68
Infiltration pattern11/31/162/454/140.041
Expansive type/not expansive type/NA
Lymphatic invasion11/32/0168/358/40.631
No/yes/NA
Venous invasion18/25/0126/401/30.041
No/yes/NA
Clinicopathological features of older patients with MSI-H CRC

Table 3 shows the clinicopathological features of patients with MSI-H CRC according to age group. The MSI-H CRC cohort was divided into two groups: An older group (≥ 71 years; mean 78.8 ± 5.3 years) and a younger group (≤ 70 years; mean 56.8 ± 10.2 years). MSI-H CRC was identified in 21 older (7.4%) and 22 younger (7.6%) patients, indicating a comparable prevalence between the two age groups.

Table 3 Clinicopathological characteristics of older and younger patients with microsatellite instability-high colorectal cancer, mean ± SD/median (range).
Characteristics
≥ 71 years (n = 21)
≤ 70 years (n = 22)
P value
Age78.8 ± 5.356.8 ± 10.2< 0.001
Sex0.763
Male/female9/12 (57.1)11/11
CEA (ng/mL)4.6 (1.0-107)2.1 (0.6-36.3)0.02
CA19-9 (U/mL)17 (2-440)10.5 (2-265)0.458
Tumor location0.00153
Right/left20/111/11
RAS18/3/013/5/40.0864
Wild/mut/NA
BRAF V600E7/14/016/2/4< 0.001
Wild/mut/NA
Histological type8/3/6/3/1/014/3/4/1/0/00.422
Tub/por/muc/med/pap/other
Mucinous component1
Yes/no15/616/6
Poorly component0.203
Yes/no9/125/17
Tumor size (mm)54.1 ± 30.649.9 ± 33.10.663
T1/5/12/34/4/13/10.454
1/2/3/4
Lymph node metastasis0.281
No/yes15/619/3
Distant metastasis0.488
No/yes20/122/0
Infiltration pattern5/15/16/16/01
Expansive type/not expansive type/NA
Lymphatic invasion3/188/140.162
No/yes
Venous invasion8/1310/120.76
No/yes
Lynch syndrome, n (%)1 (4.8)14 (63.6)< 0.001

Older patients with MSI-H CRC showed distinct molecular and clinical profiles compared with younger patients; they exhibited a significantly higher frequency of right-sided tumors (P = 0.002), BRAF mutations (P < 0.001), and higher serum CEA levels (P = 0.02) than younger patients. No significant differences in RAS mutation status, pathological factors, or other oncological characteristics were observed between the two groups. Although Lynch syndrome was diagnosed significantly more frequently in patients aged ≤ 70 years (P = 0.0001), cases suggestive of Lynch syndrome were identified in older patients.

Presumed causative genes in MSI-H CRC

The presumed causative MMR protein deficiencies in patients with MSI-H CRC are summarized in Figure 2. The older group demonstrated a significantly higher rate of MLH1 expression loss (85.7% of cases; 18/21) than the younger group (P < 0.001). Among the older patients with MLH1-deficiencies, four tested negative for BRAF mutations. By contrast, the younger age group showed a higher prevalence of MSH2 and MSH6 deficiencies. One older patient developed MSI-H despite preserved immunohistochemical expression of all four MMR proteins (MLH1, PMS2, MSH2, and MSH6).

Figure 2
Figure 2 Presumed causative mismatch repair protein deficiencies in microsatellite instability-high colorectal cancer stratified by age. The distribution of immunohistochemical loss of mismatch repair proteins is shown for the older (≥ 71 years, n = 21) and younger (≤ 70 years, n = 22) groups. Presumed causative factors were categorized based on the specific pattern of mismatch repair protein loss.

Table 4 shows the clinical and molecular profiles of older patients with MSI-H CRC exhibiting non-typical sporadic patterns. Among the 21 older patients with MSI-H, six (28.6%) exhibited non-typical profiles. Of the six cases, four (19.0%) had MLH1 deficiency and wild-type BRAF (cases 4, 5, 6, and 7), and two (9.5%) had MSH2 or MSH6 deficiency (cases 1 and 3). Although two patients with wild-type BRAF (cases 4 and 5) were subsequently confirmed to have non-Lynch syndrome via germline testing, this subgroup represents a clinically challenging population that requires further differential diagnosis.

Table 4 Clinical and molecular profiles of older patients with microsatellite instability-high colorectal cancer showing non-typical sporadic patterns.
Case
1
2
3
4
5
6
7
Age (years)80767279857680
SexMaleMaleFemaleFemaleFemaleMaleMale
Lynch syndromeNot evaluatedNot evaluatedYesNoNoNot evaluatedNot evaluated
Primary siteLower rectumCecumCecumCecumTransTransTrans
Histological typeTub2Tub1PapMucTub2MucMuc
Presumed causative genesMSH2NAMSH6MLH1MLH1MLH1MLH1
BRAF V600EWTWTWTWTWTWTWT
RASMutMutMutWTWTWTWT
Family historyMother colon cancer (unknown)Father colon cancer (unknown), brother liver cancer, cholangiocarcinoma (unknown)Father: Lung cancer, laryngeal cancer; mother: Gastric cancer (70-79 years); sister: Sigmoid colon cancer (50-59 years)Mother endometrial cancer (40-49 years). Father lung cancerDaughter: Breast cancer (60-69 years)NoneMother and brother: Cancer death (origin, year unknown)
Past cancer historyNoneNone40-49 years rectal cancer; 60-69 years endometrial cancerNoneNoneNoneNone
Amsterdam II criteriaNot metNot metNot metNot metNot metNot metNot met
Revised Bethesda GuidelinesNot evaluatedNot evaluatedMetMetNot metNot metNot evaluated
RemarksExcluded by genetic testingExcluded by genetic testing
RecurrenceDissemination, CR by ICINoneNoneDissemination, CR by ICILiver metastasis (synchronous), CR by ICINoneNone
PrognosisAlive (61.3 months)Alive (52.7 months)Alive (24.1 months)Alive (74.2 months)Alive (75.4 months)Alive (52.7 months)Alive (42.3 months)

Regarding non-MLH1 deficiencies, one case of MSH2 deficiency (case 1: An 80-year-old man) and one case of MSH6 deficiency (case 3: A 72-year-old woman) were identified. Case 3 had a history of endometrial cancer and met the Revised Bethesda Guidelines and was definitively diagnosed with Lynch syndrome. This finding underscores that even in patients aged > 70 years, specific MMR protein loss can lead to a definitive diagnosis of a hereditary syndrome that would otherwise be missed under age-restricted screening. Case 1 exemplifies this dilemma; although germline testing was not completed, the clinical and IHC profiles strongly suggest that relying strictly on age thresholds or assuming that older MSI-H cases are uniformly sporadic creates a substantial risk of missing hereditary syndromes.

DISCUSSION

This single-center retrospective cohort study investigated the clinicopathological characteristics of MSI-H CRC in a Japanese population, with a particular focus on age-stratified differences. Our findings provide critical insights into the rationale for comprehensive molecular profiling in Japan, where the rapid population aging presents unique clinical challenges. Overall, MSI-H CRC was more frequently located in the right colon, involved fewer lymph nodes and distant metastases, and generally exhibited an expansive growth pattern compared with MSS CRC. Although these general features align with those of previous western reports, our study highlights the importance of recognizing the molecular diversity within the older population with MSI-H. These findings are consistent with those of previous reports and support the notion that MSI-H CRC is a biologically distinct subtype.

Large database studies, including analyses from the National Cancer Database, have demonstrated that MSI-H CRC preferentially arises in the right-sided colon[16] and is associated with a lower incidence of lymph node and distant metastases. Similarly, multiple cohort studies and meta-analyses have reported reduced metastatic potential and favorable outcomes in patients with MSI-H CRC[17-19]. These characteristics have been attributed, at least in part, to strong host antitumor immune responses and unique tumor biology.

The presence of mucinous components and expansive growth patterns observed in MSI-H CRC in the present study was also consistent with that observed in previous histopathological reports[20]. We observed an additional tendency toward a lower frequency of venous invasion in patients with MSI-H CRC. Although reports focusing specifically on venous invasion are limited, van Zwam et al[21] have reported a lower prevalence of perineural invasion in MSI-H tumors, and suggested that reduced invasive potential and immune-mediated tumor control may suppress early invasion of vascular or neural structures. Our findings were consistent with this interpretation. Serum CEA levels were generally lower in patients with MSI-H CRC than in those with MSS CRC, although this difference was not statistically significant. This trend has been reported in previous studies and may reflect the distinct growth and dissemination patterns of MSI-H tumors[22,23].

The present study mainly focused on evaluating age-related differences in MSI-H CRC. With 70 years as the threshold, the prevalence of MSI-H CRC was nearly identical between older (7.4%) and younger (7.6%) patients. However, distinct molecular landscapes were observed between these groups; older patients showed a significantly higher prevalence of BRAF mutations and MLH1 deficiency, reflecting a predominantly sporadic pathway in older individuals[24,25]. As mentioned above, 28.6% of the older patients with MSI-H showed atypical profiles, including 19.0% (4/21) with MLH1 deficiency and wild-type BRAF V600E.

Importantly, despite this trend, we identified cases of MSH2 and MSH6 deficiencies among older patients, and one patient was definitively diagnosed with Lynch syndrome (Table 4, Case 3). This underscores the risk of age-restricted screening strategies, such as those limiting testing to patients ≤ 70 years or those fulfilling only the revised Bethesda Guidelines[11,12]. As family history is often underreported or inaccurately recalled by older patients, a comprehensive molecular evaluation remains the most reliable method for identifying hereditary cancer syndromes that may otherwise be missed. Furthermore, many older patients may have been unaware of Lynch syndrome because of its limited recognition in previous decades, even if they had early onset cancer, as depicted in Case 3.

Among the older patients with MSI-H CRC, 19.0% (4/21) exhibited MLH1 deficiency with wild-type BRAF V600E. Although these cases are often clinically dismissed as sporadic because of the patient’s age and tumor location, this subgroup may require careful evaluation to exclude Lynch syndrome. Thus, BRAF V600E status should be assessed concurrently with MSI testing, and for those exhibiting wild-type BRAF, MLH1 promoter methylation analysis should be performed[26,27]. However, in real-world clinical practice, definitive germline genetic testing is often constrained by high financial costs and the pragmatic challenges of obtaining informed consent, particularly among older populations. Many elderly patients with atypical molecular profiles remain without a genetic diagnosis. However, our findings directly challenge the assumption that older age uniformly implies sporadic disease, suggesting that these atypical cases warrant a clinical approach similar to that for Lynch syndrome. Recognizing these non-typical patterns is crucial not only for personalized surveillance of the patient but also for initiating cascade screening to protect at-risk family members. Integrating these molecular markers into routine clinical practice strategies will significantly enhance the diagnostic precision. In the context of East Asia’s rapidly aging population, such an approach is vital not only for individual patient management but also as a cornerstone of preventive medicine through cascade screening for family members at risk.

Moreover, the clinical implications of these findings extend beyond hereditary cancer detection into the era of precision medicine. Although cost-effectiveness is often cited as a reason for restricting screening in older patients[13], the clinical benefits must be reevaluated. First, immune checkpoint inhibitors have demonstrated remarkable efficacy in MSI-H CRC regardless of age[28,29]. We have previously reported successful treatment with pembrolizumab in an older patient with recurrent MSI-H CRC[30]. Although the therapeutic efficacy of these agents is well established and remains promising independent of whether the MSI-H status is attributable to Lynch syndrome, accurately characterizing the underlying etiology is crucial. Second, identifying Lynch syndrome in older patients provides life-saving opportunities for family members through cascade screening and early intervention[31]. Appropriate genetic counseling and surveillance can reduce the risk of extracolonic malignancies in affected families[32,33]. Therefore, the “cost” of reflex molecular testing should be weighed against the long-term public health benefits and the optimization of personalized treatment strategies. Moreover, identifying Lynch syndrome in older patients provides life-saving opportunities for family members through cascade screening and early intervention[34,35].

This study has some limitations. First, this was a single-center retrospective study with a limited sample size, which may have introduced selection bias and limited statistical power. Due to the small number of MSI-H cases (n = 43) and older patients (n = 21), our findings regarding the prevalence of atypical molecular profiles must be interpreted with caution and should not be overgeneralized to all older populations. Second, our cohort included only patients who underwent surgical resection for primary CRC, meaning that patients with unresectable advanced or metastatic disease were excluded. This selection bias may have affected the observed prevalence and clinical profiles of MSI-H CRC, as the molecular and biological landscapes can differ in end-stage, unresectable diseases. Third, the lack of routine MLH1 promoter methylation analysis and universal germline testing means that our “atypical” cohort likely contains a mix of late-onset sporadic cases with MLH1 methylation and true Lynch syndrome cases. Consequently, the reported prevalence of 28.6% for non-typical profiles may be overestimated. Given the real-world constraints of costs, personal data protection, and elderly patients’ reluctance to undergo genetic testing, we believe that managing this heterogeneous subgroup collectively as “potentially hereditary” is a pragmatic and safe strategy to prevent the omission of high-risk patients and their relatives from necessary surveillance. Finally, the 70-year division was based on clinical and guideline-related considerations, and alternative age thresholds may have produced different results. Therefore, our findings should be used for hypothesis generation and require validation in larger multicenter prospective studies. A definitive comparison of the prevalence of atypical MSI-H profiles between our cohort and Western populations remains challenging. This is because the detection and characterization of these subpopulations are highly dependent on country-specific healthcare systems, insurance models, and the local penetration of universal screening protocols. Therefore, the lack of identical data settings in international literature underscores the unique value of real-world datasets that reflect specific regional clinical practices. Furthermore, we did not perform a formal cost-effectiveness analysis for expanding reflex testing in older populations. However, given that universal screening is already recommended, omitting evaluation in older adults with atypical profiles may reduce the overall efficiency of screening programs. Considering the hereditary nature of Lynch syndrome, identifying these older cases is a critical long-term investment that facilitates cascade screening and early intervention for descendants, ultimately improving public health sustainability. Future studies using this cohort will focus on comprehensive immune profiling, including IHC and genomic, transcriptomic, and proteomic analyses, to further elucidate the biological heterogeneity of MSI-H CRC.

CONCLUSION

In our cohort, the prevalence of MSI-H CRC was comparable between older and younger patients. Of the older patients with MSI-H, 28.6% (6/21) exhibited molecular profiles that were inconsistent with typical sporadic patterns, including BRAF wild-type and non-MLH1 deficiencies. Therefore, older patients with MSI-H CRC should not be automatically assumed to have sporadic disease. While limited by a small sample size, these findings suggest that accurate molecular characterization, potentially incorporating reflex MLH1 methylation analysis, may be beneficial to optimize individual patient management and facilitate cascade screening for family members, warranting further validation in larger multicenter studies.

References
1.  Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409-413.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 5580]  [Cited by in RCA: 5409]  [Article Influence: 601.0]  [Reference Citation Analysis (21)]
2.  Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350-1356.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 4335]  [Cited by in RCA: 4086]  [Article Influence: 371.5]  [Reference Citation Analysis (28)]
3.  Picard E, Verschoor CP, Ma GW, Pawelec G. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Front Immunol. 2020;11:369.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 441]  [Cited by in RCA: 404]  [Article Influence: 67.3]  [Reference Citation Analysis (12)]
4.  Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609-618.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1480]  [Cited by in RCA: 1347]  [Article Influence: 64.1]  [Reference Citation Analysis (18)]
5.  Toh JWT, Phan K, Reza F, Chapuis P, Spring KJ. Rate of dissemination and prognosis in early and advanced stage colorectal cancer based on microsatellite instability status: systematic review and meta-analysis. Int J Colorectal Dis. 2021;36:1573-1596.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 11]  [Cited by in RCA: 30]  [Article Influence: 6.0]  [Reference Citation Analysis (1)]
6.  Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, Qian ZR, Morikawa T, Shen J, Meyerhardt JA, Fuchs CS, Ogino S. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105:1151-1156.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 371]  [Cited by in RCA: 350]  [Article Influence: 26.9]  [Reference Citation Analysis (8)]
7.  Cheong C, Oh SY, Kim YB, Suh KW. Differences in biological behaviors between young and elderly patients with colorectal cancer. PLoS One. 2019;14:e0218604.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 17]  [Cited by in RCA: 17]  [Article Influence: 2.4]  [Reference Citation Analysis (2)]
8.  Evrard C, Rochelle T, Martel M, Al Achkar A, Ferru A, Randrian V, Karayan-Tapon L, Tougeron D. Prognostic and Predictive Value of Microsatellite Instability Analysis in Circulating Tumor DNA Using Digital Droplet PCR for Patients With Microsatellite Instability Colorectal Cancers. Lab Invest. 2025;105:104176.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 5]  [Reference Citation Analysis (0)]
9.  Zhang J, Li S, Ma P, Zhang J, Cao Y, Liu C, Zhang X, Li Z, Li C, Zhao Y. Clinicopathological features and prognoses in younger and older patients with mismatch repair defects colorectal cancer: a retrospective comparative cohort study. J Gastrointest Oncol. 2024;15:260-270.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 3]  [Cited by in RCA: 4]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
10.  Gupta S, Provenzale D, Llor X, Halverson AL, Grady W, Chung DC, Haraldsdottir S, Markowitz AJ, Slavin TP Jr, Hampel H; CGC, Ness RM, Weiss JM, Ahnen DJ, Chen LM, Cooper G, Early DS, Giardiello FM, Hall MJ, Hamilton SR, Kanth P, Klapman JB, Lazenby AJ, Lynch PM, Mayer RJ, Mikkelson J;  CGC, Peter S, Regenbogen SE, Dwyer MA;  CGC, Ogba N. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019. J Natl Compr Canc Netw. 2019;17:1032-1041.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 137]  [Cited by in RCA: 190]  [Article Influence: 27.1]  [Reference Citation Analysis (0)]
11.  Stoffel EM, Mangu PB, Gruber SB, Hamilton SR, Kalady MF, Lau MW, Lu KH, Roach N, Limburg PJ; American Society of Clinical Oncology;  European Society of Clinical Oncology. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol. 2015;33:209-217.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 222]  [Cited by in RCA: 268]  [Article Influence: 22.3]  [Reference Citation Analysis (3)]
12.  Balmaña J, Balaguer F, Cervantes A, Arnold D; ESMO Guidelines Working Group. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2013;24 Suppl 6:vi73-vi80.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 106]  [Cited by in RCA: 114]  [Article Influence: 8.8]  [Reference Citation Analysis (2)]
13.  Peterse EFP, Naber SK, Daly C, Pollett A, Paszat LF, Spaander MCW, Aronson M, Gryfe R, Rabeneck L, Lansdorp-Vogelaar I, Baxter NN. Cost-effectiveness of Active Identification and Subsequent Colonoscopy Surveillance of Lynch Syndrome Cases. Clin Gastroenterol Hepatol. 2020;18:2760-2767.e12.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 6]  [Cited by in RCA: 17]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
14.  ACS.   AJCC Version 9 Cancer Staging System. [cited 3 May 2026]. Available from: https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/version-9/.  [PubMed]  [DOI]
15.  Japanese Society for Cancer of the Colon and Rectum. Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma: the 3d English Edition [Secondary Publication]. J Anus Rectum Colon. 2019;3:175-195.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 591]  [Cited by in RCA: 558]  [Article Influence: 79.7]  [Reference Citation Analysis (9)]
16.  Akce M, Zakka K, Jiang R, Williamson S, Alese OB, Shaib WL, Wu C, Behera M, El-Rayes BF. Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status. Front Oncol. 2021;11:592351.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 16]  [Cited by in RCA: 15]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
17.  Malesci A, Laghi L, Bianchi P, Delconte G, Randolph A, Torri V, Carnaghi C, Doci R, Rosati R, Montorsi M, Roncalli M, Gennari L, Santoro A. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res. 2007;13:3831-3839.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 203]  [Cited by in RCA: 190]  [Article Influence: 10.0]  [Reference Citation Analysis (1)]
18.  Buckowitz A, Knaebel HP, Benner A, Bläker H, Gebert J, Kienle P, von Knebel Doeberitz M, Kloor M. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer. 2005;92:1746-1753.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 221]  [Cited by in RCA: 218]  [Article Influence: 10.4]  [Reference Citation Analysis (6)]
19.  Kim CG, Ahn JB, Jung M, Beom SH, Kim C, Kim JH, Heo SJ, Park HS, Kim JH, Kim NK, Min BS, Kim H, Koom WS, Shin SJ. Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br J Cancer. 2016;115:25-33.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 144]  [Cited by in RCA: 130]  [Article Influence: 13.0]  [Reference Citation Analysis (8)]
20.  Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158:527-535.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 369]  [Cited by in RCA: 376]  [Article Influence: 15.0]  [Reference Citation Analysis (7)]
21.  van Zwam PH, Vink-Börger EM, Bronkhorst CM, de Bruine AP, van der Wurff AA, Rutten HJT, Lemmens VEPP, Nagtegaal ID, Hugen N. Prognosis of mucinous colon cancer is determined by histological biomarkers rather than microsatellite instability. Histopathology. 2023;82:314-323.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 6]  [Reference Citation Analysis (0)]
22.  Cao Y, Zhang G, Zhang J, Yang Y, Ren J, Yan X, Wang Z, Zhao Z, Huang X, Bao H, Zhou J. Predicting Microsatellite Instability Status in Colorectal Cancer Based on Triphasic Enhanced Computed Tomography Radiomics Signatures: A Multicenter Study. Front Oncol. 2021;11:687771.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 28]  [Cited by in RCA: 27]  [Article Influence: 5.4]  [Reference Citation Analysis (2)]
23.  Jakob D, Orth V, Gödde D, Zirngibl H, Ambe PC. Microsatellite instability is highly prevalent in older patients with colorectal cancer. Front Surg. 2024;11:1288061.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 4]  [Reference Citation Analysis (0)]
24.  Yearsley M, Hampel H, Lehman A, Nakagawa H, de la Chapelle A, Frankel WL. Histologic features distinguish microsatellite-high from microsatellite-low and microsatellite-stable colorectal carcinomas, but do not differentiate germline mutations from methylation of the MLH1 promoter. Hum Pathol. 2006;37:831-838.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 39]  [Cited by in RCA: 41]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
25.  Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073-2087.e3.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1824]  [Cited by in RCA: 1682]  [Article Influence: 105.1]  [Reference Citation Analysis (17)]
26.  Newton K, Jorgensen NM, Wallace AJ, Buchanan DD, Lalloo F, McMahon RF, Hill J, Evans DG. Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC). J Med Genet. 2014;51:789-796.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 54]  [Cited by in RCA: 55]  [Article Influence: 4.6]  [Reference Citation Analysis (2)]
27.  Cazzaniga L, Zanzottera C, Mannucci S, Fava F, Marabelli M, Calvello M, Feroce I, Risti M, Del Fiol Manna E, Bertario L, Serrano D, Bonanni B. MLH1 promoter hypermethylation and Lynch Syndrome: When to test for constitutional epimutations of MLH1 gene? Tumori. 2025;3008916241312530.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 3]  [Reference Citation Analysis (1)]
28.  André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT, Yoshino T, Van Cutsem E, Yang P, Farooqui MZH, Marinello P, Diaz LA Jr; KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020;383:2207-2218.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 2522]  [Cited by in RCA: 2369]  [Article Influence: 394.8]  [Reference Citation Analysis (17)]
29.  Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledeine JM, Overman MJ, Lonardi S. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2022;40:161-170.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 593]  [Cited by in RCA: 569]  [Article Influence: 142.3]  [Reference Citation Analysis (11)]
30.  Takeda T, Shonaka T, Shimazaki R, Adachi Y, Otani M, Matsushita W, Tani C, Hasegawa K, Sumi Y. Peritoneal Recurrence of Cecal Cancer with Specific Imaging Findings and Shrinkage after Treatment with Pembrolizumab. J Anus Rectum Colon. 2022;6:67-71.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 1]  [Reference Citation Analysis (0)]
31.  Petterson AT, Garbarini J, Baker MJ. Universal screening of colorectal tumors for lynch syndrome: a survey of patient experiences and opinions. Hered Cancer Clin Pract. 2024;22:18.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 2]  [Reference Citation Analysis (0)]
32.  Shawki S, Kalady MF. Recent advances in understanding Lynch syndrome. F1000Res. 2016;5:2889.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 2]  [Cited by in RCA: 1]  [Article Influence: 0.1]  [Reference Citation Analysis (1)]
33.  Kim JY, Byeon JS. Genetic Counseling and Surveillance Focused on Lynch Syndrome. J Anus Rectum Colon. 2019;3:60-68.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 4]  [Cited by in RCA: 13]  [Article Influence: 1.9]  [Reference Citation Analysis (0)]
34.  Salikhanov I, Heinimann K, Chappuis P, Buerki N, Graffeo R, Heinzelmann V, Rabaglio M, Taborelli M, Wieser S, Katapodi MC. Swiss cost-effectiveness analysis of universal screening for Lynch syndrome of patients with colorectal cancer followed by cascade genetic testing of relatives. J Med Genet. 2022;59:924-930.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1]  [Cited by in RCA: 25]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]
35.  Ito S, Xicola RM, Sra M, Potnis KC, Singh V, Gershkovich P, Stites E, Gibson J, Krumholz HM, Llor X, Goshua G. Cost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening. Clin Gastroenterol Hepatol. 2025;23:2328-2338.e9.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 4]  [Reference Citation Analysis (0)]
Footnotes

Peer review: Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Oncology

Country of origin: Japan

Peer-review report’s classification

Scientific quality: Grade B, Grade C

Novelty: Grade B, Grade C

Creativity or innovation: Grade B, Grade C

Scientific significance: Grade B, Grade C

P-Reviewer: Suda T, MD, PhD, Japan; Wang ZC, Associate Chief Physician, MD, China S-Editor: Wu S L-Editor: A P-Editor: Zhao YQ

Write to the Help Desk